Amoxapine

Depression, Generalized Anxiety Disorder, Agitation + 4 more

Treatment

20 Active Studies for Amoxapine

What is Amoxapine

Amoxapine

The Generic name of this drug

Treatment Summary

Amoxapine is a type of antidepressant called a tricyclic antidepressant (TCA). It is related to the antipsychotic drug loxapine and works to increase serotonin and norepinephrine levels in the brain. This can help improve mood in people with depression. Amoxapine is used to treat depression, anxiety, and mixed symptoms of depression and anxiety. Common side effects of TCAs include sedation, low blood pressure, blurred vision, dry mouth, constipation, and urinary retention.

Amoxapine

is the brand name

image of different drug pills on a surface

Amoxapine Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Amoxapine

Amoxapine

1992

5

Effectiveness

How Amoxapine Affects Patients

Amoxapine is a type of antidepressant that is known to have a calming effect. It works differently than other antidepressants and has been shown to reduce the uptake of certain chemicals in the brain (nor-epinephirine and serotonin) and block the response of dopamine receptors to dopamine. It does not work as a monoamine oxidase inhibitor. Clinical studies have shown that amoxapine starts working faster than other antidepressants, such as amitriptyline and imipramine.

How Amoxapine works in the body

Amoxapine works by preventing the body from reabsorbing the chemical messengers norepinephrine and serotonin.

When to interrupt dosage

The suggested dosage of Amoxapine is subject to the determined illness, for instance Neurotic depression, Psychotic Depression and Agitation. The amount of dosage depends on the method of delivery (e.g. Oral or Tablet) featured in the table beneath.

Condition

Dosage

Administration

Agitation

, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg

Tablet, , Oral, Tablet - Oral

Depression

, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg

Tablet, , Oral, Tablet - Oral

Generalized Anxiety Disorder

, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg

Tablet, , Oral, Tablet - Oral

Mental Depression

, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg

Tablet, , Oral, Tablet - Oral

Psychotic Depression

, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg

Tablet, , Oral, Tablet - Oral

Mental Depression

, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg

Tablet, , Oral, Tablet - Oral

Neurotic depression

, 50.0 mg, 25.0 mg, 100.0 mg, 150.0 mg

Tablet, , Oral, Tablet - Oral

Warnings

Amoxapine Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Amoxapine.

Common Amoxapine Drug Interactions

Drug Name

Risk Level

Description

Acepromazine

Major

Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Amoxapine is combined with Aclidinium.

Alfuzosin

Major

Amoxapine may increase the hypotensive activities of Alfuzosin.

Amisulpride

Major

Amoxapine may increase the antipsychotic activities of Amisulpride.

Aripiprazole

Major

Amoxapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

Amoxapine Toxicity & Overdose Risk

Taking too much amoxapine can have serious side effects, such as seizures, coma, abnormal acid levels in the body, and kidney failure. Seizures are the most common symptom, and can lead to a medical emergency called status epilepticus. In rare cases, kidney failure can develop a couple days after overdosing.

image of a doctor in a lab doing drug, clinical research

Amoxapine Novel Uses: Which Conditions Have a Clinical Trial Featuring Amoxapine?

819 active clinical trials are investigating the potential of Amoxapine in treating Neurotic Depression, Agitation and Mental Despondency.

Condition

Clinical Trials

Trial Phases

Psychotic Depression

0 Actively Recruiting

Generalized Anxiety Disorder

181 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 4, Phase 1, Phase 3

Mental Depression

0 Actively Recruiting

Mental Depression

0 Actively Recruiting

Neurotic depression

0 Actively Recruiting

Depression

305 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Agitation

3 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Amoxapine Reviews: What are patients saying about Amoxapine?

5

Patient Review

9/13/2020

Amoxapine for Depression

This drug was more effective than similar treatments I've tried in the past. At first, I experienced periods of involuntary yawning, but I quickly got used to it. My concentration while on this medication was amazing.

5

Patient Review

12/8/2008

Amoxapine for Depression

5

Patient Review

8/3/2011

Amoxapine for Depression

Amoxapine has been a complete game-changer for me since I started taking it in 1981.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about amoxapine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the brand name for amoxapine?

"Amoxapine is a tricyclic antidepressant that is used to treat symptoms associated with depression, anxiety, or agitation."

Answered by AI

What is amoxapine used to treat?

"This medicine is used to treat the symptoms of depression by increasing levels of certain chemicals in the brain. This medicine is a tricyclic antidepressant (TCA) and is available only with a doctor's prescription."

Answered by AI

Is amoxapine an antipsychotic?

"The drug Amoxapine is marketed as an antidepressant, though it has similar in-vitro profiles, receptor occupancies, and preclinical effects to atypical antipsychotics. Amoxapine has shown to be effective as an atypical antipsychotic in open trials."

Answered by AI

What are the side effects of amoxapine?

"popular antidepressants can cause a number of

side effects, including nausea, drowsiness, weakness or tiredness, nightmares, dry mouth, skin more sensitive to sunlight than usual, changes in appetite or weight, and constipation."

Answered by AI

Clinical Trials for Amoxapine

Image of Northwestern University in Evanston, United States.

Sleep and Dreaming Practices for Anxiety

18+
All Sexes
Evanston, IL

People spend approximately one-third of their lives asleep, yet sleep is often underused as an opportunity to support psychological well-being. Contemplative traditions, including Tibetan Dream Yoga, have developed practices that use waking imagination and lucid dreaming to explore perception, awareness, and habitual patterns of thinking. Recent advances in sleep monitoring, dream communication, and lucid dream induction now make it possible to study these practices using scientific methods. This study is a randomized controlled trial designed to examine the feasibility and effects of a Dream-Yoga-inspired intervention compared with an active control condition. The intervention combines waking and dreaming practices that are adapted for individuals without prior experience and delivered using virtual reality-based training and home sleep technology. The program is designed to be scalable and culturally neutral, without requiring prior knowledge of contemplative or religious traditions. The primary goals of the study are to characterize sleep and waking neurophysiology associated with Dream-Yoga-inspired practices and to evaluate whether participation is associated with changes in sleep-related brain activity and cognitive processes. Outcomes include measures of lucid dreaming, sleep physiology, and waking cognitive and perceptual processes. Anxiety will be assessed as an exploratory outcome to examine whether participation may be associated with changes in emotional experience. This study is not designed to provide treatment for anxiety or other clinical conditions. Results from this study will help inform the development of scalable sleep-based mental training approaches and guide future research on the use of dreaming and sleep practices to support psychological health and well-being

Phase < 1
Waitlist Available

Northwestern University (+1 Sites)

Image of University of Michigan in Ann Arbor, United States.

Virtual Reality for Depression in Multiple Sclerosis

18+
All Sexes
Ann Arbor, MI

This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems. The study hypotheses include: * The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions. * The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.

Recruiting
Has No Placebo

University of Michigan

Hala Darwish, PhD

Apple Inc.

Have you considered Amoxapine clinical trials?

We made a collection of clinical trials featuring Amoxapine, we think they might fit your search criteria.
Go to Trials
Image of Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry in Charleston, United States.

Mindfulness Training for Depression

18 - 70
All Sexes
Charleston, SC

This NIH-funded single-arm pilot tests the feasibility, acceptability, and preliminary effects of embedding brief guided mindfulness practice (via the Healthy Minds smartphone app) into the inter-session intervals of clinically administered accelerated intermittent theta-burst stimulation (aiTBS) for major depressive disorder (MDD). Participants receive aiTBS as standard clinical care at MUSC; the research intervention is daily guided mindfulness practice during the aiTBS course. Outcomes include feasibility/acceptability, changes in state mindfulness and hedonic tone (Day 0 to Day 5), perceived ease of meditation, trait mindfulness at 4 and 12 weeks, and durability of antidepressant response (PHQ-9) at 4 and 12 weeks.

Waitlist Available
Has No Placebo

Medical University of South Carolina (MUSC), Brain Stimulation Laboratory Institute of Psychiatry

Clayton Olash, MD

Have you considered Amoxapine clinical trials?

We made a collection of clinical trials featuring Amoxapine, we think they might fit your search criteria.
Go to Trials
Image of Worcester Recovery Center and Hospital in Worcester, United States.

Changing Lives and Changing Outcomes-9 for Serious Mental Illness

18+
All Sexes
Worcester, MA

People with serious mental illness (depression, bipolar, and schizophrenia spectrum disorders) have high rates of repeated criminal legal involvement and psychiatric hospitalizations. Longstanding research shows that in addition to treating clients' symptoms of mental illness, targeting risk factors for legal involvement can help reduce their chances of future incarcerations. Because hospitals are becoming increasingly forensic, treatment programs that address both mental illness and risk factors for legal involvement may be especially helpful in a state hospital setting, like Worcester Recovery Center and Hospital (WRCH). This treatment study offers an adjunctive 9-session intervention, Changing Lives and Changing Outcomes-9 (CLCO-9), for patients at WRCH; this program is designed to help people with serious mental illness who are involved in the legal system increase their awareness of their mental health and reduce their chances of future legal involvement. The investigators are proposing a treatment study testing the use of the CLCO-9 group intervention with patients with serious mental illness with current or previous criminal legal involvement at Worcester Recovery Center and Hospital (WRCH). The study has three aims: 1. Evaluate feasibility, fidelity, and patient satisfaction during the implementation of the CLCO-9 group treatment at WRCH 2. Evaluate CLCO-9's effectiveness on improving patient's self-reported mental health, and behavioral indicators of mental health and risk factors for legal involvement 3. Explore changes in WRCH clinicians' knowledge and attitudes about treating risk factors for criminal legal involvement. To test these aims, the research team will employ a two-phase study. In the first phase, the researchers will implement the intervention and make necessary adjustments to maximize the success of the implementation. In the second phase, the researchers will evaluate the treatment program's effectiveness in producing change from pre- to post-treatment. All patient participants in this study will receive the intervention. The projected sample size is about 20 treatment completers and 4 to 8 group leaders.

Waitlist Available
Has No Placebo

Worcester Recovery Center and Hospital

Faith Scanlon, PhD

Have you considered Amoxapine clinical trials?

We made a collection of clinical trials featuring Amoxapine, we think they might fit your search criteria.
Go to Trials